When tested on mice, the drug was found effective in improving maternal and foetal outcomes, reducing blood pressure, preventing major organ damage in the expectant mother, improving foetal weight and decreasing foetal mortality. MirZyme claims to be the first company to develop products that can interfere with this molecule’s production, offering the possibility for women to be able to protect their babies and in some cases themselves from the condition. It is thought to stem from an overproduction of a molecule from the placenta, which results in damage to the blood vessels of the pregnant woman. Early signs include high blood pressure and protein in the urine. Pre-eclampsia is usually detected during the second half of pregnancy or soon after birth and can lead to serious complications if it is not found during midwife appointments. MirZyme’s new drug, MZe786, is a single pill to be taken once a day by women deemed at risk of the condition, from the 20th week of pregnancy. It is granted to medicines that address the needs of patients with life-threatening and unmet medical needs, with a view to getting the drug to the market as quickly as possible. The passport was established in January 2021 to expedite access to essential new drugs at the height of the Covid pandemic. MirZyme Therapeutics has been awarded an innovative licensing and access pathway (ILAP), or so-called innovation passport, by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Globally, it affects between 2% and 8% of pregnancies and kills up to half a million babies and 100,000 women a year.
Pre-eclampsia endangers the lives of thousands of expectant mothers and their babies in the UK each year, and has no therapeutic options.
0 kommentar(er)
